Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $43.60.

COLL has been the subject of a number of recent analyst reports. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th.

Collegium Pharmaceutical Trading Up 3.5 %

NASDAQ:COLL opened at $31.58 on Friday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 13.61 and a beta of 0.82. Collegium Pharmaceutical has a 52 week low of $28.39 and a 52 week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a 50 day moving average of $31.02 and a 200 day moving average of $34.06.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $736,000. Hillsdale Investment Management Inc. boosted its stake in shares of Collegium Pharmaceutical by 1.0% during the 4th quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company’s stock worth $3,329,000 after acquiring an additional 1,100 shares in the last quarter. Summit Global Investments acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $232,000. Teacher Retirement System of Texas increased its stake in shares of Collegium Pharmaceutical by 16.6% in the 4th quarter. Teacher Retirement System of Texas now owns 9,568 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 1,363 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of Collegium Pharmaceutical by 593.7% during the 4th quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company’s stock worth $1,923,000 after buying an additional 57,455 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.